Fecal transplant to help eradicate stubborn Helicobacter pylori infection

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This interventional study examines whether regulating the gut microbiota through transanal fecal microbiota transplant can contribute to eradicating refractory H. pylori infection. Eligible participants are adults 18–70 who have failed guideline-recommended therapies at least four times and have related gastric conditions. The trial focuses on a gut-modulating approach rather than another antibiotic regimen, with safety precautions and exclusion criteria to minimize risk. The lead site is Sichuan Provincial People’s Hospital in Chengdu, China. The study is in Phase 4, reflecting evaluation in a real-world, post-approval context.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* 1\. Ages 18-70
* 2\. Hp infection treatment failed ≥4 times with guidelines-recommended therapies
* 3\. Patients with early gastric cancer, peptic ulcer, gastric MALT lymphoma, atrophic gastritis and other diseases requiring the eradication of Hp.

Exclusion Criteria:

* 1\. Antibiotics and bismuth were taken within 4 weeks before this treatment; Or had taken PPI, H2 receptor antagonist, P-CAB within 2 weeks prior to treatment;
* 2\. Pregnant or lactating women;
* 3\. Those who are allergic to the investigational drugs used in this test or have contraindications;
* 4\. Participated in other drug trials within 3 months before the treatment of this trial;
* 5\. There are other serious diseases that affect the evaluation of this study at the same time, or they cannot correctly express their own complaints and cannot cooperate;
* 6\. Subjects with dysphagia;
* 7\. Patients with malignant tumors, serious concomitant diseases, severe ulcer bleeding or perforation;
* 8\. Patients judged by the investigator to be unsuitable for clinical trials.
* 9\. Those who do not want to sign the informed consent for the study.

Where it's running

• Sichuan Provincial People's Hospital
  Chengdu, Sichuan, China Recruiting

Study contacts

• Study coordinator: Gao Caiping, Doctor
• Email: gaocaip@126.com
• Phone: 17708130286

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Fecal-guided simplified vonoprazan plus clarithromycin first-line therapy for H. pylori

  We are testing whether a two-drug regimen of vonoprazan plus clarithromycin clears H. pylori in adults whose fecal PCR shows no clarithromycin resistance mutations.

  Recruiting Peking University First Hospital · Beijing, Beijing Municipality · NCT07439445

• Bismuth-amoxicillin-vonoprazan triple therapy versus bismuth-based quadruple therapy for H. pylori infection

  This will test whether a 14-day bismuth-amoxicillin-vonoprazan triple therapy works better and is as safe as a 14-day bismuth-based quadruple therapy for adults with H. pylori infection.

  Recruiting Kaohsiung Medical University · Kaohsiung City · NCT07358130

• P-CABs plus bismuth quadruple treatment for Helicobacter pylori infection

  This study tests whether using potassium-competitive acid blockers (P-CABs) in bismuth-containing quadruple therapy works better and is safe for adults with H. pylori infection.

  Recruiting Qilu Hospital of Shandong University · Jinan · NCT07285096

• Bismuth versus no bismuth for treating H. pylori-related stomach and duodenal ulcers in children

  This project will try adding bismuth to standard antibiotic and PPI treatment to see if it helps clear H. pylori and heal ulcers in children.

  Recruiting Can Tho University of Medicine and Pharmacy · Can Tho · NCT07260006

• Tegoprazan 50 mg twice daily plus amoxicillin versus vonoprazan 20 mg twice daily plus amoxicillin for H. pylori eradication

  This trial tests whether a 14-day tegoprazan plus amoxicillin regimen works as well as a vonoprazan plus amoxicillin regimen to cure Helicobacter pylori infection in adults.

  Recruiting Phase 2/3 First People's Hospital of Hangzhou · Hangzhou, Zhejiang · NCT07242456

• Potassium-competitive acid blocker versus proton pump inhibitor with bismuth quadruple therapy for H. pylori infection

  This trial tests whether a potassium-competitive acid blocker works better than a proton pump inhibitor as part of bismuth quadruple therapy to cure H. pylori infection in adults.

  Recruiting Tanta University · Tanta, El-Gharbia · NCT07165444

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.